Abstract
A QSAR study is reported to predict the binding affinity of a set of 81 modulators for both of human estrogen receptor α and β (ERα and ERβ). In this study, the derived QSAR models were built by forward stepwise multilinear regression (MLR) and nonlinear radial basis function neural networks (RBFNN), respectively. The statistical characteristics of the external test set provided by multiple linear model (R2=0.814, F=61.277, RMS=0.5461 for ERα; R2=0.600, F=21.039, RMS=0.6707 for ERβ) indicated satisfactory stability and predictive ability of the model built. The predictive ability for ERβ of RBFNN model is somewhat superior: R2=0.7691, F=32.012, RMS=0.5764, and the similar result was obtained for ERα of the test set: R2=0.7950, F=54.131 RMS=0.3120. Overall, the appropriate results proved the models to be meaningful and useful to predict and virtual screen of the derivatives with high binding activity.
Keywords: Quantitative Structure-Activity Relationships (QSAR), hERα, hERβ, Multiple Linear Regression (MLR), Radial Basis Function Neural Networks (RBFNN), Binding activity.
Letters in Drug Design & Discovery
Title:Prediction of the Estrogen Receptor Binding Affinity for both hERα and hERβ by QSAR Approaches
Volume: 11 Issue: 3
Author(s): Changliang Deng, Xuanxuan Chen, Hongying Lu, Xin Yang, Feng Luan and Maria Natalia Dias Soeiro Cordeiro
Affiliation:
Keywords: Quantitative Structure-Activity Relationships (QSAR), hERα, hERβ, Multiple Linear Regression (MLR), Radial Basis Function Neural Networks (RBFNN), Binding activity.
Abstract: A QSAR study is reported to predict the binding affinity of a set of 81 modulators for both of human estrogen receptor α and β (ERα and ERβ). In this study, the derived QSAR models were built by forward stepwise multilinear regression (MLR) and nonlinear radial basis function neural networks (RBFNN), respectively. The statistical characteristics of the external test set provided by multiple linear model (R2=0.814, F=61.277, RMS=0.5461 for ERα; R2=0.600, F=21.039, RMS=0.6707 for ERβ) indicated satisfactory stability and predictive ability of the model built. The predictive ability for ERβ of RBFNN model is somewhat superior: R2=0.7691, F=32.012, RMS=0.5764, and the similar result was obtained for ERα of the test set: R2=0.7950, F=54.131 RMS=0.3120. Overall, the appropriate results proved the models to be meaningful and useful to predict and virtual screen of the derivatives with high binding activity.
Export Options
About this article
Cite this article as:
Deng Changliang, Chen Xuanxuan, Lu Hongying, Yang Xin, Luan Feng and Cordeiro Natalia Dias Soeiro Maria, Prediction of the Estrogen Receptor Binding Affinity for both hERα and hERβ by QSAR Approaches, Letters in Drug Design & Discovery 2014; 11 (3) . https://dx.doi.org/10.2174/15701808113109990067
DOI https://dx.doi.org/10.2174/15701808113109990067 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Benzodiazepines, Amphetamines, Testosterone, and Sildenafil as New Candidate Drugs for Sexual Interest, Desire and/or Arousal Disorder
Current Psychopharmacology The Upshot of PI3K Inhibitors as Anticancer Arsenal: A Short Review
Current Bioactive Compounds Distinguished Photons: A Review of In Vivo Spectral Fluorescence Imaging in Small Animals
Current Pharmaceutical Biotechnology LINE-1 Methylation is Associated with an Increased Risk of Ischemic Stroke in Men
Current Neurovascular Research Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Ultrasound-Based Multimodal Molecular Imaging and Functional Ultrasound Contrast Agents
Current Pharmaceutical Design Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry Role of Lycopene in the Control of ROS-Mediated Cell Growth: Implications in Cancer Prevention
Current Medicinal Chemistry Current Developments in the Analysis of Proteomic Data: Artificial Neural Network Data Mining Techniques for the Identification of Proteomic Biomarkers Related to Breast Cancer
Current Proteomics γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
Current Topics in Medicinal Chemistry Targeting Water in the Brain: Role of Aquaporin-4 in Ischemic Brain Edema
Current Drug Targets Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes
Current Signal Transduction Therapy Illuminating microRNA Transcription from the Epigenome
Current Genomics Metabolic Features of Melanoma: A Gold Mine of New Therapeutic Targets?
Current Cancer Drug Targets Novel Platelet Signalling Pathways Identified via Proteomics
Current Proteomics Roles of Retinoic Acid in Induction of Immunity and Immune Tolerance
Endocrine, Metabolic & Immune Disorders - Drug Targets Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer
Current Molecular Medicine Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets